Conclusions
MIBC
Neoadjuvant treatment with camrelizumab and GC regimen demonstrated preliminary anti‐tumor activity for MIBC patients with manageable safety profiles. The study met its primary endpoint, and the following randomized trial is ongoing.In this multicenter, single‐arm study, we investigated the anti‐tumor activity and safety of neoadjuvant camrelizumab plus gemcitabine and cisplatin for MIBC patients. The pCR was 43.3% in evaluable patients. Our study met its primary endpoint, and a randomized trial is currently underway.
Sujun Han, Zhigang Ji and Junhui Jiang contributed equally to this work.